Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
ACTIVE_NOT_RECRUITING
Status
Conditions
Interventions
- DRUG: Nivolumab
- DRUG: Ch14.18/CHO
Sponsor
University Hospital Southampton NHS Foundation Trust
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]